CL2021000329A1 - Compuestos útiles en terapia del vih - Google Patents

Compuestos útiles en terapia del vih

Info

Publication number
CL2021000329A1
CL2021000329A1 CL2021000329A CL2021000329A CL2021000329A1 CL 2021000329 A1 CL2021000329 A1 CL 2021000329A1 CL 2021000329 A CL2021000329 A CL 2021000329A CL 2021000329 A CL2021000329 A CL 2021000329A CL 2021000329 A1 CL2021000329 A1 CL 2021000329A1
Authority
CL
Chile
Prior art keywords
useful compounds
hiv therapy
compounds
hiv
therapy
Prior art date
Application number
CL2021000329A
Other languages
English (en)
Inventor
John Franklin Miller
David Temelkoff
Emile Johann Velthuisen
La Rosa Martha Alicia De
Lita Suwandi
B Narasimhulu Naidu
Original Assignee
Viiv Healthcare Co
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co, Glaxosmithkline Ip No 2 Ltd filed Critical Viiv Healthcare Co
Publication of CL2021000329A1 publication Critical patent/CL2021000329A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se refiere a compuestos de las fórmulas (I), (Ia), (II) y (IIa), sales de los mismos, composiciones farmacéuticas de los mismos, así como procedimientos para tratar o prevenir el VIH en sujetos.
CL2021000329A 2018-08-09 2021-02-08 Compuestos útiles en terapia del vih CL2021000329A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862716494P 2018-08-09 2018-08-09

Publications (1)

Publication Number Publication Date
CL2021000329A1 true CL2021000329A1 (es) 2021-09-03

Family

ID=68072882

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000329A CL2021000329A1 (es) 2018-08-09 2021-02-08 Compuestos útiles en terapia del vih

Country Status (15)

Country Link
US (1) US20220117993A1 (es)
EP (1) EP3833437A1 (es)
JP (1) JP2021534112A (es)
KR (1) KR20210044806A (es)
CN (1) CN112789085A (es)
AR (1) AR115936A1 (es)
AU (1) AU2019317810A1 (es)
BR (1) BR112021002169A2 (es)
CA (1) CA3108635A1 (es)
CL (1) CL2021000329A1 (es)
IL (1) IL280660A (es)
MA (1) MA53280A (es)
MX (1) MX2021001612A (es)
TW (1) TW202023650A (es)
WO (1) WO2020031131A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA128041C2 (uk) 2019-01-25 2024-03-20 Браун Юніверсіті Спосіб лікування пов'язаного з віком запалення у пацієнта
BR112021017604A2 (pt) 2019-03-06 2021-11-16 Glaxosmithkline Ip No 2 Ltd Compostos úteis na terapia para hiv
TWI862645B (zh) 2019-07-27 2024-11-21 美商布里生物科學股份有限公司 腺苷衍生物及包含其之醫藥組合物
EP4010349A1 (en) * 2019-08-08 2022-06-15 GlaxoSmithKline Intellectual Property (No. 2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
TWI845826B (zh) * 2020-03-20 2024-06-21 美商基利科學股份有限公司 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法
EP4281083A4 (en) 2021-01-25 2025-01-01 Brii Biosciences, Inc. COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS
KR20230132476A (ko) * 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CN1533390A (zh) 2001-03-19 2004-09-29 СҰҩƷ��ҵ��ʽ���� 包含三氮杂螺[5.5]十一烷衍生物作为活性成分的药物组合物
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2008143846A1 (en) * 2007-05-14 2008-11-27 Rfs Pharma, Llc Azido purine nucleosides for treatment of viral infections
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
US9822138B2 (en) * 2015-08-10 2017-11-21 Merck Sharp & Dohme Corp. Antiviral beta-amino acid ester phosphodiamide compounds
US20190185508A1 (en) * 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
JP2021534112A (ja) 2021-12-09
US20220117993A1 (en) 2022-04-21
BR112021002169A2 (pt) 2021-05-04
WO2020031131A1 (en) 2020-02-13
MA53280A (fr) 2021-11-17
IL280660A (en) 2021-03-25
KR20210044806A (ko) 2021-04-23
TW202023650A (zh) 2020-07-01
MX2021001612A (es) 2021-05-13
EP3833437A1 (en) 2021-06-16
CA3108635A1 (en) 2020-02-13
AU2019317810A1 (en) 2021-02-25
CN112789085A (zh) 2021-05-11
AR115936A1 (es) 2021-03-17

Similar Documents

Publication Publication Date Title
CL2021000329A1 (es) Compuestos útiles en terapia del vih
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
CO2020007218A2 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
UY36648A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
MX2024004921A (es) Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos.
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
UY36212A (es) Moduladores de receptores tipo toll para el tratamiento del vih
MX2015011478A (es) Compuestos de amida para el tratamiento de vih.
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2019002240A1 (es) Dendrímeros terapéuticos.
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CR20180091A (es) 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
CR20170157A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7